Premium
Use of Angiotensin‐Converting Enzyme Inhibitors as Monotherapy and in Combination with Diuretics and Calcium Channel Blockers
Author(s) -
Cheng Angela,
Frishman William H.
Publication year - 1998
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1998.tb05784.x
Subject(s) - pharmacology , angiotensin converting enzyme , captopril , calcium channel , pharmacokinetics , ace inhibitor , medicine , drug , pharmacodynamics , calcium , blood pressure
Angiotensin‐converting enzyme (ACE) inhibitors have earned an important place in medical therapy since their discovery about two decades ago. This family of drug has grown tremendously since the introduction of captopril in 1981. There are currently more than 14 ACE inhibitors in the world and 9 are available in the United States. Although these agents share many similarities, they differ in their pharmacokinetic properties, approved indications, and cost. This paper provides guidance for selection of ACE inhibitors by examining the pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost of these agents. Combination products of ACE inhibitors with either diuretics or calcium channel blockers also are reviewed.